Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations

被引：0
|
作者：
Zhang, Q. [1 ]
Ke, L. [1 ]
Huang, S. [2 ]
Yang, Y. [1 ]
He, T. [1 ]
Sun, H. [3 ]
Wu, Z. [1 ]
Zhang, X. [4 ]
Lv, W. [1 ]
Hu, J. [1 ]
Ye, J. [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China
[3] Zhejiang Univ, Taizhou Hosp, Taizhou, Peoples R China
[4] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Aumolertinib; Adjuvant; Uncommon EGFR mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.07
引用
收藏
页码：S555 / S556
页数：2
相关论文
共 50 条
  • [1] HRQoL with Adjuvant Aumolertinib in Patients with Resected Stage IB-IIIA EGFR Mutant Non Small Cell Lung Cancer
    Hu, W.
    Mao, Z.
    Cheng, N.
    Huang, J.
    Tang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S563 - S564
  • [2] Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations
    Wen, Miaomiao
    Wang, Lei
    Wang, Xuejiao
    Yang, Sanhu
    Sun, Ying
    Xia, Jinghua
    Zhang, Yanning
    Zhang, Zhipei
    Huang, Lijun
    Jiang, Tao
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (12) : 686 - 693
  • [3] Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer
    Scagliotti, GV
    Fossati, R
    Torri, V
    Crinó, L
    Giaccone, G
    Silvano, G
    Martelli, M
    Clerici, M
    Cognetti, F
    Tonato, M
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19): : 1453 - 1461
  • [4] A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer.
    Keller, SM
    Adak, S
    Wagner, H
    Herskovic, A
    Komaki, R
    Brooks, BJ
    Perry, MC
    Livingston, RB
    Johnson, DH
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (17): : 1217 - 1222
  • [5] Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations
    Shao, F.
    Zhang, Q.
    Cheng, W.
    Liu, N.
    Fang, H.
    Fang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S651 - S651
  • [6] Adjuvant therapy in completely resected non-small-cell lung cancer
    Giorgio V. Scagliotti
    Silvia Novello
    Current Oncology Reports, 2003, 5 (4) : 318 - 325
  • [7] Adjuvant chemotherapy in completely resected non-small-cell lung cancer
    Pisters, KMW
    Le Chevalier, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) : 3270 - 3278
  • [8] Adjuvant Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer
    Suehisa, Hiroshi
    Toyooka, Shinichi
    ACTA MEDICA OKAYAMA, 2009, 63 (05) : 223 - 230
  • [9] Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer
    Naim Younes, R.
    Gross, J. L.
    Abrao, F. C.
    Rodrigues Pereira, J.
    MINERVA CHIRURGICA, 2013, 68 (02) : 169 - 174
  • [10] Role of adjuvant therapy in resected stage II/IIIA non-small-cell lung cancer
    Movsas, B
    ONCOLOGY-NEW YORK, 2002, 16 (01): : 90 - +
12345